ReviewEvidence-based complementary and alternative medicine : eCAM2016
Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence.
Review in Evidence-based complementary and alternative medicine : eCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06228638 (CognivAiD Real-World Evidence Clinical Registry), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CognivAiD Real-World Evidence Clinical Registry
Who cites it
28 citing papers in PubMed, 74 citations in OpenAlex.
- Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine.Chinese journal of integrative medicine · 2020Trial
- Cognitive-Enhancing Effects of Bioactive Compounds and Traditional Herbal Medicines in Elderly Patients with Metabolic Syndrome.Biomolecules · 2026Review
- The Role of Oxidative Stress and Inflammation in the Pathogenesis and Treatment of Vascular Dementia.Cells · 2025Review
- Huperzine A ameliorates neurological deficits after spontaneous subarachnoid hemorrhage through endothelial cell pyroptosis inhibition.Acta biochimica et biophysica Sinica · 2024Article
- Notoginsenoside R1 ameliorates the inflammation induced by amyloid‑β by suppressing SphK1‑mediated NF‑κB activation in PC12 cells.Molecular medicine reports · 2024Article
- The Protective Effect of Vitamin D on Dementia Risk in Hemodialysis Patients.Life (Basel, Switzerland) · 2023Article
- Oral administration of an integrative supplement (CogniCapsOpen veterinary journal · 2023Article
- Article
- Early intervention and adding effective doses of EGb761 likeFrontiers in neurology · 2023Article
- Analysis of Potential Mechanism of Herbal Formula Taohong Siwu Decoction against Vascular Dementia Based on Network Pharmacology and Molecular Docking.BioMed research international · 2023Article
- A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia.Aging medicine (Milton (N.S.W)) · 2022Article
- Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia.International journal of molecular sciences · 2022Review
- "Malancha" [Biomolecules · 2022Review
- Article
- Crocins for Ischemic Stroke: A Review of Current Evidence.Frontiers in pharmacology · 2022Review
- Molecular mechanism of Epimedium in the treatment of vascular dementia based on network pharmacology and molecular docking.Frontiers in aging neuroscience · 2022Article
- Systems Biology and Chemoinformatics-Based Strategies to Explore the Biological Mechanism of Fugui Wenyang Decoction in Treating Vascular Dementia Rats.Oxidative medicine and cellular longevity · 2021Article
- Bioactive Compounds and Traditional Herbal Medicine: Promising Approaches for the Treatment of Dementia.Degenerative neurological and neuromuscular disease · 2021Review
- Efficacy and safety of butylphthalide as adjunctive therapy for vascular dementia: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia is a leading cause of mental and physical disability. Vascular dementia (VaD) is the second most common cause of dementia after Alzheimer's disease (AD) constituting 10-15% of the dementia population. Currently there are no approved pharmaceutical options for VaD and the conventional anti-AD therapies provide only modest, short-term relief of symptoms associated with VaD. Herbal medicines have been used for the management of dementia-like symptoms for centuries and may provide viable therapies for VaD due to their multicomponent and multitarget approach. This review is designed to provide an updated overview on the current status of herbal medicine research, with an emphasis on Chinese herbal medicine, for the treatment of VaD or dementia. A case study is also provided to demonstrate the development process of a novel standardized complex herbal formulation for VaD. The article reveals some preliminary evidence to support the use of single and complex herbal preparations for VaD and dementia. Multiple issues in relation to clinical and preclinical research have been identified and future research directions are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.